Anavex Life Sciences Corp (AVXL)

[georgejjl]

Don't forget about Anavex 2-73 for rearing epileptic seizures

ANAVEX 2-73 for Epilepsy

ANAVEX 2-73 exhibited dose-dependent significant anti-convulsive action by providing almost complete to complete protection from tonic seizures in three established seizure models.

In maximum electroshock (MES)-induced convulsions, 30 mg/kg ANAVEX 2-73 provided 90% protection. In pentylenetetrazol (PTZ)-induced convulsions, the same dose provided 85% protection. In a semicarbazide (SCZ) model, the same dose was able to delay the tonic seizures from 56.9 seconds to 99.2 seconds. In (PTZ)-induced convulsions, 60 mg/kg ANAVEX 2-73 had a long-lasting effect with 100 % seizure protection after both 4 and 6 hours, respectively.
ANAVEX 2-73 demonstrated robust synergistic effect in combination with three drugs currently on the market.

With Ethosuximide (ETS) (Zarontin®), a first-generation antiepileptic drug, the combination of 10 mg/kg ANAVEX 2-73 and 200 mg/kg ETS provided 80% protection in MES-induced convulsions, while no protection at all was observed at the same dose of ETS alone. In the (PTZ)-induced convulsion model, the combination of 10 mg/kg ANAVEX 2-73 metabolite and 200 mg/kg of first line anti-epileptic drug Valproic acid (VPA) (Depakene®) showed 92% protection from tonic seizures, compared with modest 12.5% protection when 200 mg/kg VPA was administered on its own. In combination with the newer-generation anti-epileptic drug gabapentin (Neurontin®), ANAVEX 2-73 metabolite also showed a statistically strong effect in the reduction of seizures, compared to gabapentin alone. In the MES test, the combination of 5 mg/kg ANAVEX 2-73 metabolite with 100 mg/kg gabapentin resulted in 90% protection from tonic seizures as compared to 40% protection with 100 mg/kg gabapentin alone.
In order to test for potential side effects often seen with epilepsy drugs currently on the market, ANAVEX 2-73 was assessed in preclinical depression as well as mobility models. In both the forced (Porsolt) swim test and the open-field test, ANAVEX 2-73 showed clear anti-depressant effects and no signs of sedation. In the chimney test, ANAVEX 2-73 yielded no statistically significant motor impairment within the effective dose range.


About Epilepsy

Epilepsy is the most common serious neurological disorder, affecting people of all ages. It is a term used for recurring seizure disorder, a condition that is characterized by the tendency for an individual to have repeated nervous seizures (interruption of normal brain activity). Epilepsy is considered to be a spectrum disorder that can cause other health problems, including cognitive impairments, with a wide range of seizure types and control varying from person to person. The greatest unmet needs in epilepsy remain the inadequate control of seizures that occur in 20% to 30% of drug-treated epilepsy patients, effective treatments for related orphan indications like Dravet or Lennox-Gastaut Syndrome, rare forms of epilepsy, and therapies with reduced co-morbidity, translating into a significant market opportunity. The global epilepsy market was estimated at $4.2 billion in 2012 and is expected to grow to $5.35 billion by 2022, with more than 50% of sales coming from the United States.

http://www.anavex.com/?post_type=news&p=1460

Good luck and GOD bless,

George